ENESDENewsletter →
Shotlee
Get the app
📖Complete Guide✅Updated 2026🔬Evidence-Based

Mazdutide Guide

GCG/GLP-1 Dual Agonist Weight Loss 2026

Complete guide to Mazdutide (IBI362) — Innovent

Download on theApp Store
Get it onGoogle Play
Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
⌄
ACTIVE MEDICATIONS
MazdutideB12
MAZDUTIDE
🔥 14
2
days away
Thursday · 7.5mg
⌄
Medication Supply
Mazdutide
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Levels
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
Today
ACTIVE MEDICATIONS
MazdutideRetatrutide
0mg2.7mg5.4mg
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
⌄
ACTIVE MEDICATIONS
MazdutideB12
MAZDUTIDE
🔥 14
2
days away
Thursday · 7.5mg
⌄
Medication Supply
Mazdutide
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Levels
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
Today
ACTIVE MEDICATIONS
MazdutideRetatrutide
0mg2.7mg5.4mg
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
01BACKGROUND

What Is Mazdutide Guide?

Mazdutide (development code IBI362) is a long-acting, once-weekly glucagon-like peptide-1 (GLP-1) and glucagon (GCG) co-agonist developed by Innovent Biologics. The dual mechanism targets two complementary metabolic pathways: GLP-1 agonism reduces appetite and food intake, while GCG agonism dramatically increases energy expenditure and drives hepatic fat oxidation. This combination addresses obesity from both sides of the energy equation simultaneously — reducing calorie intake while increasing calorie burning. The GLORY Phase 3 trials in China were completed in 2024, establishing Mazdutide as one of the most clinically advanced GCG/GLP-1 candidates globally.

02MECHANICS

Key Biohacking Mechanics

1
Activates hypothalamic appetite centers
2
Slows gastric emptying → prolonged satiety
3
Enhances glucose-dependent insulin release
4
Reduces food cravings and total caloric intake
5
Increases basal metabolic rate (energy expenditure)
6
Promotes hepatic fat oxidation (reduces liver fat)
7
Drives lipolysis in adipose tissue
8
Unique to this drug class vs GLP-1/GIP
9
14.5% avg body weight loss at 3mg dose
10
48-week trial in adults with obesity
11
Significant liver fat reduction (MASLD benefit)
12
Improved blood pressure and lipids
13
86% liver fat reduction in NASH/MASLD subgroups
14
Systolic BP reduced by 6-8 mmHg
15
Significant triglyceride reduction
16
Waist circumference reduction >12cm
03DEEP DIVE

Expected Dosing Schedule

Starter dose to minimize GI side effects

First therapeutic escalation step

Mid-range dose showing good efficacy

Maximum dose — achieved 14.5% weight loss in GLORY

Note: Final approved dosing may vary. Follow your prescriber's guidance. Use Shotlee to log each weekly dose and monitor your progress.

04WHAT TO TRACK

Side Effects

01
⚠️
Common Side Effects
Nausea (most common, dose-dependent). Vomiting. Diarrhea. Constipation. Injection site reactions
02
🔬
Glucagon-Related Notes
Transient blood glucose elevation possible. Managed by GLP-1 component counterbalance. GI adverse events similar to GLP-1 monotherapy. No unexpected cardiac signals in trials. Low discontinuation rate
05TIMELINE

Development Timeline

2022-2023:
Phase 2 trials established safety and efficacy dose range
2024:
Phase 3 GLORY trials completed — 14.5% weight loss at 3mg
2025:
NMPA (China) regulatory submission for obesity indication
2025-2026:
Potential China approval and global partnership/licensing discussions
06WHAT TO TRACK

Vital Protocol FAQs

01
🧬
How does Mazdutide\'s GCG agonism differ from tirzepatide\'s GIP agonism?
Tirzepatide adds GIP receptor activation which enhances GLP-1 effects and improves insulin sensitivity. Mazdutide adds glucagon receptor activation which drives energy expenditure and liver fat oxidat
02
🔬
Is Mazdutide available outside China?
Currently Mazdutide is only available in China after completing GLORY trials there. International rights have not been finalized. A global partnership or licensing deal would be needed for FDA/EMA fil
03
📱
Can I track a Mazdutide protocol with Shotlee?
Yes — Shotlee supports custom weekly injectable tracking. Log your Mazdutide doses, track your weight loss progress, and monitor side effects weekly with the free Shotlee app.
07FAQ

Guide FAQs

Complete guide to Mazdutide (IBI362) — Innovent

Yes. Shotlee supports tracking Mazdutide doses, side effects, and health metrics. It is free to use.

Free · Always

Track Your Mazdutide Protocol in Shotlee

Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.

Download on theApp Store
Get it onGoogle Play

📚References & sources

🔗Keep exploring

All Guides
→
Trackers
→
Compare
→
Start tracking